Evidence map›Paper›PMID 40638599›Full record

ReviewPLoS pathogens2025

Pelota: A double-edged sword in virus infection.

Xue Li, Xueping Zhou, Fangfang Li

Abstract readReview
In one paragraph

Review in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Elucidation of theFrontiers in plant science · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xue LiState Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing, China.
Xueping ZhouState Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing, China.ORCID 0000-0001-5311-7331
Fangfang LiState Key Laboratory for Biology of Plant Diseases and Insect Pests, Institute of Plant Protection, Chinese Academy of Agricultural Sciences, Beijing, China.ORCID 0000-0001-7695-7958

Funding

National Natural Science Foundation of China
6 · The paper itself

Abstract

Pelota, a conserved ribosome rescue factor involved in mRNA surveillance, has emerged as a pivotal player in host-virus arms race. Beyond its canonical role in maintaining translational fidelity via No-Go Decay and Non-Stop Decay pathways, Pelota exhibits a dual function during viral infection-serving either as a restriction factor or as a susceptibility element depending on the virus species and their hosts. In DNA virus infections, notably with geminiviruses, a natural mutation in Pelota confers recessive resistance in tomato and pepper probably by impairing viral protein translation, offering valuable insights for resistance breeding. Conversely, in RNA virus infections, Pelota usually restricts viral propagation through RNA quality control, yet can also promote viral replication by facilitating ribosome recycling and translation. This paradox reflects a fine-tuned balance in host-virus adaption and co-evolution. Additionally, pelota mutations can modulate immune signaling pathways, with some alleles triggering enhanced resistance or autoimmunity phenotypes in plants. Meanwhile, viruses have evolved counterdefense strategies, including targeted degradation or SUMOylation interference, to subvert the Pelota's function. Together, these findings position Pelota as a double-edged sword in viral infection, highlighting its potential as a novel target for antiviral strategies through precise genetic manipulation.

Indexed as

Plant DiseasesPlant ProteinsVirus DiseasesHost-Pathogen InteractionsPlant Proteins

Identifiers

PMID40638599
PMCPMC12244479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.